Literature DB >> 28144710

Selective venous vasodilator properties of the analgesic metamizole (dipyrone) in a human ex vivo model-implications for postoperative pain management.

Markus Hoenicka1, Hagen Gorki2, Karl Traeger3, Andreas Liebold2.   

Abstract

Metamizole (dipyrone) is a first-line, non-opioid analgesic used for postoperative pain management. Clinical data and animal experiments indicate a possible vasodilator action of this drug. We investigated the effects of metamizole on human artery and vein tone in an ex vivo model to assess potential contributions to venous pooling. Excess segments of bypass grafts were harvested during coronary artery bypass grafting procedures. Tensions were measured in an organ bath for 120 min after adding metamizole to the preconstricted vessels. Contribution of endothelium was assessed in endothelium-denuded vessels, and indometacin was used to identify cyclooxygenase-mediated effects. Internal mammary arteries (n = 6) constricted after addition of 1, 3, and 10 μM metamizole and remained constricted at the lower doses. Transient constrictions also occurred in saphenous veins (n = 20), but veins relaxed below solvent controls after 20 min at all concentrations. Endothelium removal (n = 12) and cyclooxygenase inhibition (n = 12) suppressed the vasoconstrictor effect but not the vasodilator effect. Metamizole and its metabolites display counteracting effects on blood vessel tone ex vivo. The vasoconstrictor effect is mediated by cyclooxygenase-derived products. The net effect is site-specific, resulting in a selective venous vasodilator action. This may exacerbate unwanted venous pooling during postoperative pain therapy.

Entities:  

Keywords:  Analgesia; Cyclooxygenase; Vasodilation; Venous pooling

Mesh:

Substances:

Year:  2017        PMID: 28144710     DOI: 10.1007/s00210-017-1347-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  24 in total

1.  Stimulated prostacyclin release by conduits used for coronary artery bypass grafting.

Authors:  J Bonatti; W Dichtl; E A Dworzak; H Antretter; F Unger; B Puschendorf; O E Dapunt
Journal:  Thorac Cardiovasc Surg       Date:  1998-04       Impact factor: 1.827

Review 2.  The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations.

Authors:  W M Bennett; W L Henrich; J S Stoff
Journal:  Am J Kidney Dis       Date:  1996-07       Impact factor: 8.860

3.  Preliminary studies on oxidative decomposition of dipyrone solutions.

Authors:  D D Dubash; W E Moore
Journal:  J Pharm Sci       Date:  1972-03       Impact factor: 3.534

4.  Metamizol acts as an ATP sensitive potassium channel opener to inhibit the contracting response induced by angiotensin II but not to norepinephrine in rat thoracic aorta smooth muscle.

Authors:  Fermín Valenzuela; Sebastián García-Saisó; Cristina Lemini; Rafael Ramírez-Solares; Horacio Vidrio; Víctor Mendoza-Fernández
Journal:  Vascul Pharmacol       Date:  2005-08       Impact factor: 5.773

5.  [Reducing blood pressure with Dipyron (novaminsulfone sodium)].

Authors:  M Zoppi; R Hoigné; M F Keller; F Streit; T Hess
Journal:  Schweiz Med Wochenschr       Date:  1983-11-26

6.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.

Authors:  Patricia M Kearney; Colin Baigent; Jon Godwin; Heather Halls; Jonathan R Emberson; Carlo Patrono
Journal:  BMJ       Date:  2006-06-03

7.  Novel bioactive metabolites of dipyrone (metamizol).

Authors:  Tobias Rogosch; Christian Sinning; Agnes Podlewski; Bernhard Watzer; Joel Schlosburg; Aron H Lichtman; Maria G Cascio; Tiziana Bisogno; Vincenzo Di Marzo; Rolf Nüsing; Peter Imming
Journal:  Bioorg Med Chem       Date:  2011-11-25       Impact factor: 3.641

Review 8.  Clinical pharmacokinetics of dipyrone and its metabolites.

Authors:  M Levy; E Zylber-Katz; B Rosenkranz
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

9.  Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital.

Authors:  G Heinemeyer; H J Gramm; W Simgen; R Dennhardt; I Roots
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Characterization of the role of physicochemical factors on the hydrolysis of dipyrone.

Authors:  Hakan Ergün; Daniel A C Frattarelli; Jacob V Aranda
Journal:  J Pharm Biomed Anal       Date:  2004-05-28       Impact factor: 3.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.